Business Context and Reporting Period
Company: Humacyte, Inc. (HUMA)
Filing Type: Form 8-K (Current Report)
Date of Report: October 6, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering of common stock and warrants.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: 28,436,018 shares of Common Stock and warrants to purchase up to 28,436,018 shares.
- Offering Price: $2.11 per share and accompanying warrant.
- Expected Closing Date: October 8, 2025.
- Placement Agent Fee: 5.75% of gross proceeds.
- Expense Reimbursement: Up to $100,000 for legal and other expenses.
- Warrant Terms: Exercise price of $2.11; exercisable 180 days after issuance; expiration on April 7, 2031.
Note: The filing text does not provide a clear value for total gross proceeds, revenue, profit, cash flow, margins, or existing debt levels.
Material Changes and Agreements
The primary material change is the execution of the Securities Purchase Agreement and Placement Agent Agreement with D. Boral Capital LLC. Key contractual terms include:
- Lock-up Period: The Company agreed not to issue additional common stock or equivalents for 30 days from the agreement date, subject to exceptions.
- Beneficial Ownership Limitation: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (or 9.99% with consent) of outstanding shares.
- Tail Financing: The Placement Agent is entitled to 6.0% of gross proceeds from any subsequent financing consummated within six months (or 12 months for certain investors) if the investor was introduced during this offering.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to an effective shelf registration statement (Form S-3) filed in September 2025. A press release regarding the pricing was issued on October 7, 2025.
Risks and Contingencies:
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Dilution: The issuance of 28.4 million shares and corresponding warrants will result in significant dilution to existing shareholders.
- Legal Disclaimer: The agreements contain customary representations and warranties but are not intended as factual disclosures for the public; investors should refer to annual and quarterly reports for operational status.
Investor Verification Checklist
- Verify the final closing of the offering on or after October 8, 2025.
- Confirm the total gross proceeds raised and the net proceeds after deducting the 5.75% placement fee and expenses.
- Review the updated share count and fully diluted capitalization post-offering.
- Assess the Company's current cash runway and burn rate in light of the new capital raised.
- Monitor for any "Tail Financing" transactions within the next 6 to 12 months that may incur additional fees.